Medical Officer's Comment: As stated above, the investigators did have the choice of decreasing the dosage of ciprofloxacin when sensitivity results were available. A review of NDA 19 – 847/S-8 revealed the following with regards to dosing:

"Patients were dosed based upon their estimated creatinine clearance, and the antimicrobial susceptibility of the causative organism according to the following schedule":

<table>
<thead>
<tr>
<th>CrCl</th>
<th>A (Fully susceptible)</th>
<th>B (Moderately susceptible)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 70 mL/min</td>
<td>Ciprofloxacin 400 bid Imipenem 500 q6</td>
<td>Ciprofloxacin 400 tid Imipenem 1g q8</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin 400 bid Imipenem 500 q8</td>
<td>Ciprofloxacin 400 tid Imipenem 500 q6</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin 300 bid Imipenem 500 q12</td>
<td>Ciprofloxacin 400 q12 Imipenem 500 q8</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin 250 q12 Imipenem 250 q12</td>
<td>Ciprofloxacin 300 q12 Imipenem 500 q12</td>
</tr>
</tbody>
</table>

All patients were started on schedule B or high dose and changes were made based on investigators clinical assessments. If renal insufficiency developed, an unblinded individual (research pharmacist) could have made dosage adjustments based on CrCl.

Although the protocol called for bacteriologic eradication at the early (3 – 5 day post-therapy) follow-up to be the primary efficacy variable, the RMO disagreed and utilized clinical response as the primary efficacy variable. The RMO provided this analysis at both the early and late follow-up visits.

As per the RMO "For patients in both groups, almost all of the treatment duration was on regimen B; the mean duration of regimen B was 9.5 days for the ciprofloxacin group and 8.8 days for the imipenem group (total mean duration of therapy was 10.5 days). 2% of the ciprofloxacin patients received regimen A only and 18% received both A and B. On the imipenem arm, 82% of patients received regimen B only. 1% regimen A only and 17% both. 76% of the clinically evaluable ciprofloxacin patients and 72% of the clinically evaluable imipenem patients received only the B regimen.

Based on the above information, the MO disagrees with the sponsor’s contention that a significant number of patients received the lower dose. Clinical response rates for this trial were noted previously. The RMO did not provide a separate analysis of response by regimen.

The MO agreed with Pfizer’s determination that ciprofloxacin dosage was adjusted for renal function. It is correct that 24% of the ciprofloxacin-treated patients had elevations of BUN during the study. There is no information available from the ciprofloxacin MOR as to how often dosage adjustments were made.

The sponsor states that no adjustments were made on the ciprofloxacin arms of the trovafloxacin studies. This is correct. However, it is merely speculative to assume that since adjustments were not made, that patients with creatinine elevations had by default higher ciprofloxacin doses, approximating the 400 tid level.

There is no evidence that the currently approved dose of ciprofloxacin for severe nosocomial pneumonia is superior to the previously approved dose.

There are no studies comparing the efficacy and safety of twice a day IV ciprofloxacin with three times a day ciprofloxacin. In the absence of such studies, it is impossible to claim that the TID dosing (even if it had been consistently used in the pivotal study) is more effective than the BID
dosing, which was extensively used to treat nosocomial pneumonia for years. In any event, it is unlikely that any reasonably sized clinical trial could ever show a meaningful difference between the twice daily and three times daily dosing of ciprofloxacin in severe nosocomial pneumonia. It is generally believed that the underlying clinical condition is the most important driver for clinical outcome in this entity. In a disease where mortality is generally 20-60%, it is likely that such a clinical trial would have to be enormous (and clinically undoable) to show a difference in the two regimens.

**Medical Officer's Comment:** Again the sponsor’s response is speculative. Within the context of the ciprofloxacin SNDA there were 6 smaller studies (European), that indicated a clear increase in clinical success rates when progressively higher ciprofloxacin doses were utilized. These studies included many types of infections including NP. There are no large trials however that have compared the 2 regimens. Without a doubt however, ciprofloxacin 400 mg tid was studied in a well-designed trial within the context of the SNDA and was shown to be superior to a good comparator regimen.

There are theoretical reasons to question the benefits of the dosing method used for ciprofloxacin in the pivotal study.

Beyond a certain minimum level, there is no evidence in either ciprofloxacin studies or in the literature to show that progressively greater amounts of antibiotic result in progressively greater efficacy. Although it may be commonly believed (or at least practiced, even among some Infectious Disease specialists) that 'if some works, more is better', there is no evidence, for example, that antibiotic levels 20 times the MIC for an organism are more clinically efficacious than 10 times. Ciprofloxacin, like all quinolones concentrates 5-15 fold over serum levels in lung tissue, already giving levels at twice daily dosing that are substantially above those needed to kill most organisms.

If one were concerned about inadequate dosing, three times a day ciprofloxacin might not be any more effective than twice a day dosing. The three times daily dosing with 400mg does not result in substantially higher peak levels of antibiotic. Many people believe that with quinolones it is the peak level that is important for organism killing. From this viewpoint, to improve efficacy it would have made more sense to use a larger dose (i.e. 600mg individual dose, or more) rather than simply adding a dose. However, Bayer may have been concerned about the tolerance profile, which appears to have been a concern with the original IV ciprofloxacin development and approval. In any event, there are no clinical data to show that three doses a day are more effective than two.

**Medical Officer’s Comment:** The MO is unaware of the argument of “more is better”. The motivation behind the design of the ciprofloxacin SNDA is not in question at this time. As stated above, the regimen was efficacious. Any other conclusions drawn about the effectiveness of the higher dose regimen as opposed to the lower dose are merely speculative given the absence of additional clinical data.

The primary rationale for the use of additional ciprofloxacin in the single pivotal study to support the 'severe nosocomial pneumonia' claim probably related to spectrum weaknesses and resistance issues that are irrelevant to the dosing used in the trovafloxacin study.

It was, and remains a common belief in the medical community that a ciprofloxacin dose of 400mg BID is not adequate to treat Streptococcus pneumoniae infections, which was also the subject of an FDA advisory committee meeting. Indeed, under the 'lower respiratory tract infection' indication, the current package insert states that ciprofloxacin is not considered first line therapy for presumed or confirmed infections due to Streptococcus pneumoniae. We believe one of the primary reasons for the TID dosing in the pivotal study that Bayer used to claim severe nosocomial pneumonia was that they studied severe pneumonia, not exclusively nosocomial pneumonia, and included a large number of patients with community acquired pneumonia and potential Streptococcus pneumoniae infections. It is likely that investigators were very
uncomfortable with the prospect of treating patients with severe community acquired pneumococcal pneumonia with BID dosing.

There has also been concern over development of resistance during therapy with ciprofloxacin in nosocomial pneumonia, particularly with infections due to *Pseudomonas aeruginosa*. One thought has been that more antibiotic might reduce the incidence of resistance, apart from any effect on clinical efficacy. This was generally known to be a problem with ciprofloxacin dosed at 400mg twice daily, and it is likely that Bayer preferred that a higher dose of ciprofloxacin be used as monotherapy, rather than that a second (non-Bayer) antibiotic be added in an attempt to answer this criticism. Indeed, Bayer's interest in monotherapy with ciprofloxacin rather than combined therapy was the key design feature of the pivotal study. As this seems to be one of the few indications in infectious diseases where one can respectably advocate the use of more antibiotic rather than less, it is likely that Bayer was also quite comfortable with this approach.

However, the primary use of monotherapy for pseudomonal pneumonia is in contrast to essentially all published recommendations for how severe nosocomial pneumonia should be treated, including those of the American Thoracic Society (2).

These issues driving a higher ciprofloxacin dose are not relevant to the trovafloxacin study. Since community acquired pneumonia was not enrolled, the presence of *Streptococcus pneumoniae* was not an issue for the ciprofloxacin arm. Additionally, Pfizer agrees with ATS that at least for infections due to *Pseudomonas aeruginosa*, dual therapy should be used, as was done in the #113 study. Although evidence that dual therapy improves clinical outcome is hard to come by, there is general consensus that at least it is useful to reduce development of resistance (2).

**Medical Officer's Comment**: Once again the sponsor's comments are speculative and refer to the motivation of ciprofloxacin's sponsor. The MO agrees that ciprofloxacin is not first line therapy for CAP associated with *Streptococcus pneumoniae*. The MO points out however, that although the ciprofloxacin SNDA was intended to evaluate both CAP and NP, only 44/205 ITT ciprofloxacin patients actually had CAP. Thus the study was compromised mostly of patients with NP.

The MO is unable to comment on Bayer's motivation to pursue the TID dosing. The MO disagrees with Pfizer's statement with regards to how NP should be treated. There is no clear documentation in the literature at this time with regards to the number of anti-microbials necessary to treat NP. Most commonly in clinical practice, more than one agent is utilized. This decision is clearly practitioner driven and based on a variety of factors such as severity of disease as well as local susceptibility and infection control issues.

There are other issues in the study that supported the use of ciprofloxacin in severe nosocomial pneumonia that detract from its strength:

-- The study excluded patients with 'resistant' organisms, while the trovafloxacin studies did not.
-- The primary endpoint was bacterial eradication and not clinical outcome.
-- In the published report, it is very difficult to actually understand the analysis. For example, the intent to treat group excluded 25% of randomized patients for reasons that are not well explained.
-- As noted above, there was considerable downward dose adjustment of ciprofloxacin that took place in the study, so that the significance of the higher dose is not clear.
-- One of the stated rationales for the higher dose was the presence of resistant organisms (such as *Pseudomonas aeruginosa*) but one of the conclusions of the study was that dual therapy was needed for pseudomonal infections, thus drawing into question the reason for the higher dose.
-- In spite of the above, the manuscript concluded that monotherapy was adequate, however the monotherapy hypothesis was not tested in the study, since both treatment arms were monotherapy regimens.

**Medical Officer's Comment**:

- Patients in the ciprofloxacin SNDA could have been excluded if a resistant pathogen was isolated.
- This did not occur in the trovafloxacin trials. MO agrees with Pfizer.
• The primary endpoint as per protocol was bacteriologic efficacy and not clinical response. However, the RMO utilized clinical response at the EOS as the primary efficacy variable and the approval for ciprofloxacin in severe NP was based on these analyses.

• Approximately 25% of the randomized patients were excluded from the clinical trial for well-documented reasons. Specifically, of the 402 randomized patients, 229 were unevaluable for long-term efficacy. The primary reasons for being unevaluable in the ciprofloxacin group were “no causative organisms” (30), “inadequate sputum specimens” (18), “resistant pre-therapy organisms” (20), and “no EOS visit” (12).

• Pfizer's conclusion that there was considerable downward dose adjustment of ciprofloxacin is merely speculative.

• The sponsor's determination of the rationale of the study is also speculative. The conclusion in the ciprofloxacin SNPDA was that ciprofloxacin was superior to the comparator in the treatment of severe NP; however, the subset of patients with Pseudomonas aeruginosa had lower eradication and clinical response rates. 33% of the isolates developed resistance on the ciprofloxacin arm as compared to 53% on the imipenem arm. The conclusion in the ciprofloxacin SNPDA was that neither ciprofloxacin nor imipenem could be recommended as monotherapy for patients with Pseudomonas aeruginosa at least in the initial phase of treatment.

• The conclusion was that ciprofloxacin was effective as a monotherapy with the exception of the aforementioned cases. It should be noted that the addition of IV vancomycin and metronidazole was allowed by-protocol and other antimicrobial usage was prohibited. This was generally adhered to.

As true monotherapy, trovafloxacin may be superior to ciprofloxacin.

Because of the lack of anaerobic activity, additional blinded antibiotics (metronidazole or clindamycin) had to be added to the ciprofloxacin arm. Overall, in the two trovafloxacin studies of nosocomial pneumonia, 22% of patients on comparative agents received additional study antibiotics (aztreonam, vancomycin, clindamycin, metronidazole), while only 11% of trovafloxacin patients required additional antibiotics (p<0.001) (table 3.2 in study reports for #113 and #137). Additionally, there is a trend to less development of resistance by Pseudomonas aeruginosa in trovafloxacin recipients (see prior response regarding severe nosocomial pneumonia).

Medical Officer's Comment: These data were presented previously. Certainly and as allowed by protocol, more patients received additional anaerobic coverage on the comparator arm. The MO does not disagree with the sponsor's statements although the conclusion that trovafloxacin is more effective as true monotherapy has not been adequately shown to the reviewer's satisfaction. The premise of monotherapy is to do away with the need for additional anaerobic and aerobic coverage.

Conclusions

Ciprofloxacin was in fact previously approved for use in nosocomial pneumonia under the broader terminology of 'lower respiratory tract infections'. The original ciprofloxacin application contained pneumonia data drawn largely from nosocomial pneumonia patients, many of whom were severely ill by any criteria. Ciprofloxacin was broadly used to treat nosocomial pneumonia under the original indication and dosing. There is no evidence that the new dosing scheme has led to any clinical benefits.

As already noted, at the time that the trovafloxacin Phase 3 studies were designed and begun, neither ciprofloxacin, nor any other agent, were approved for nosocomial pneumonia, as such. Ciprofloxacin was clearly one of the most commonly used agents for treatment of nosocomial pneumonia, and after discussion with FDA, Pfizer elected to use it as a comparative agent at the dose then approved for treatment of "lower respiratory tract infection", which was a commonly
used dose for treatment of nosocomial pneumonia. Pfizer could not predict what approvals might occur in the future, and could have been criticized for using a larger than approved dose as an attempt to bias adverse event results or other factors such as convenience or cost in favor of trovafloxacin, as now the study is criticized for potential efficacy bias in favor of trovafloxacin for having used the approved and commonly used dose of the comparator. In spite of this, the data clearly show that trovafloxacin is effective in the treatment of severe nosocomial pneumonia, and may effect other advantages, such as simpler treatment regimens, less development of resistance, and reduced risk of drug interactions.


Medical Officer's Conclusion: The sponsor adequately demonstrated comparable efficacy with ciprofloxacin in a population of patients with severe NP as defined by ATS criteria.

The issue of the adequacy of the comparator regimen and specifically the use of a lower dose of ciprofloxacin (400 bid) as opposed to the approved 400 mg tid was also addressed. The MO determined that the sponsor's response was primarily speculative with regards to ciprofloxacin's sponsor's motivation as well as with regards to the analyses of the results. The MO does not disagree with the sponsor that the dosage of ciprofloxacin utilized in the current trials was that which was approved at the time, however the higher dosage was that which received approval for the indication. This approval was granted while the trovafloxacin trials were ongoing.

The MO believes that an approval for severe NP should be issued only if trovafloxacin was found to be superior to the ciprofloxacin regimen. This however, was not the case. In the pivotal, blinded study, trovafloxacin was equivalent to ciprofloxacin but not superior. In study 154-137, trovafloxacin was numerically superior (statistical significance not achieved), to the ceftazidime/ciprofloxacin regimen however, that trial was an open study, and therefore the results may be biased. Equivalent efficacy in the severely ill subset was shown between trovafloxacin and the comparator regimens in both studies.

In the absence of clear superiority, the MO continues to recommend that trovafloxacin be approved for mild to moderate NP caused by Escherichia coli, Haemophilus influenzae, and Pseudomonas aeruginosa.

Pfizer's Recommendation for Nosocomial Pneumonia Indication Labeling for Pseudomonas aeruginosa Infections:

Pfizer believes the current statement in the proposed package insert regarding use of additional therapy in infections due to Pseudomonas aeruginosa, with minor modification, is the most appropriate approach and does not favor a statement that strongly directs a specific approach to medical therapy for several reasons:

There is little evidence in the literature and none in the trovafloxacin studies that dual therapy for nosocomial pneumonia due to Pseudomonas aeruginosa infections results in better clinical outcomes.

Indeed, in the trovafloxacin studies, the trend was in the opposite direction. To our knowledge, there is only a single report in the literature that shows dual therapy is clinically beneficial, and then only in bacteremic pseudomonal nosocomial pneumonia (1). Because there is no proof that additional therapy is beneficial in most cases of nosocomial pneumonia due to Pseudomonas aeruginosa, we do not believe a strongly directive statement is appropriate.

Medical Officer's Comment: The MO agreed with the sponsor's statement regarding the dearth of evidence in the medical literature with regards to the requirement that dual therapy be utilized in patients with NP. The MO also agreed that in the trovafloxacin studies that no conclusions could be drawn as to
the need for dual therapy in the subgroup of patients with NP caused by Pseudomonas aeruginosa. Clinical outcome was not affected either adversely or beneficially.

Package inserts should reflect the data submitted that secured the approval:

Neither study #113 (trovafloxacin vs. ciprofloxacin) nor study #137 (trovafloxacin vs. ceftazidime) required additional antipseudomonal therapy at any time during the study. Indeed, protocol #113 prohibited additional therapy unless Pseudomonas aeruginosa was positively identified on a culture, and even in that case, it was left to the clinician's judgment as to whether additional therapy should or should not be added, depending upon all the factors present in these complex cases. Protocol #137 only allowed additional antipseudomonal therapy for identified cases in the comparative arm, although as noted in the study report, it was added in some cases to the trovafloxacin arm also. In fact, only about 50% of trovafloxacin patients who had Pseudomonas aeruginosa identified on a culture actually received additional antipseudomonal therapy in these studies. Those receiving the additional therapy did not receive any benefit compared to those who did not. Since the trovafloxacin studies did not require additional therapy, patients did not uniformly receive it, and patients did not demonstrably benefit when they received it, we do not believe a strongly directive statement is appropriate.

**Medical Officer's Comment:** The MO reminds the reader that as per the study report of protocol 154 – 137 and the CRFs, 8 trovafloxacin-treated patients and 17 ceftazidime/ciprofloxacin-treated patients received adjunctive aminoglycosides when Pseudomonas aeruginosa was documented. 5/8 and 10/17 of these patients were clinically evaluable as per the sponsor. This is slightly more than 50% of the trovafloxacin patients. 4 of these cases were clinical failures.

The MO agreed that patients with nosocomial pneumonia caused by Pseudomonas aeruginosa had conflicting results and that no definitive conclusions could be drawn.

There is no precedent in antibiotic package inserts for strongly directed practice recommendations unless they reflect actual study circumstances.

The only strongly directive package insert that we are aware of is for Zosyn, which states that "initial presumptive treatment of patients with nosocomial pneumonia should start with Zosyn...PLUS AN AMINOGLYCOSIDE." It goes on to say that if Pseudomonas aeruginosa is not isolated, the additional therapy may be stopped. However, this statement simply reflects how the pivotal study was actually conducted. All patients received both Zosyn AND aminoglycoside from the initial dose, and it was a requirement that all patients with identified Pseudomonas aeruginosa continue the aminoglycoside (2). This approach seems to have been taken because an earlier study of Zosyn monotherapy failed, as mentioned in the package insert. This is quite different from the trovafloxacin studies. What is clear is that the original proposed statement for the trovafloxacin package insert is more specific and consistent with published guidelines (3) than that in any other package insert.

**Medical Officer's Comment:** The MO agreed with the above with regards to the Zosyn® package insert.

Package inserts should not be used to direct medical practice in the absence of compelling medical evidence

The question of which medical practice is best for patients with nosocomial pneumonia, or a subset of these patients, is controversial, to say the least, and one best left to the larger medical community. It is in fact a controversial subject due to the lack of compelling data on which to base recommendations. Although the American Thoracic Society has published a consensus statement on this subject (3), the Infectious Disease Society of America has different views on a number of the issues, and is assembling another guideline (personal communication Lionel Mandell). We believe it would be a mistake to mandate a particular additional therapy, only to have that superseded by newer data or newer recommendations.
We believe that reminding physicians of the prerogative to use dual therapy in instances of nosocomial pneumonia due to *Pseudomonas aeruginosa* infection is useful and that this is appropriately accomplished with the original wording. However, we would have no objection to an added direct reference to the ATS Guidelines:

"NOSOCOMIAL PNEUMONIA caused by [organism list]. As with other antibiotics, treatment of nosocomial infections due to *Pseudomonas aeruginosa* may require combination therapy, as recommended in the American Thoracic Society consensus statement for treatment of hospital acquired pneumonia (3)."


2. Zosyn Summary Basis of Approval.


**Medical Officer’s Comment:** The MO agrees with the sponsor that the labeling should contain information reflecting actual antimicrobial study circumstances. The outcomes in both protocols were conflicting and the numbers too small to be able to draw definite conclusions. The MO cannot advocate or disagree with the addition of a second agent in patients with nosocomial pneumonia due to *Pseudomonas aeruginosa*. However, the MO points out that trovafloxacin will be used in the empirical treatment of patients before culture results are available.

The following statement drafted by the MTL, "Nosocomial pneumonia (mild to moderate) caused by *Escherichia coli*, *Pseudomonas aeruginosa*, or *Haemophilus influenzae*. As with other antimicrobials, where *Pseudomonas aeruginosa* is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated." most accurately reflects study circumstances as well as current medical opinion and should be added to the labeling in both the I and U section as well as the D and A.

On 12/9/97, additional analyses for the NP indication were requested to address whether trovafloxacin was superior in severely ill patients vs. the comparator arms. Specifically, it was requested that Pfizer provide clinical efficacy tables (EOS = TOC) for both studies separately and combined (Pfizer clinically evaluable population, severe patients only as defined by mutually acceptable ATS criteria), for patients with and without concomitant antimicrobial therapy (all concomitant antimicrobial agents, including clindamycin, metronidazole, vancomycin, aztreonam and aminoglycosides). The question as expressed by this request: “Was trovafloxacin alone superior to ciprofloxacin/comparator alone or in combination with other agents in patients with severe disease only?”

This information was provided by the sponsor on 12/9/97 in the form of several tables sent by FAX. These tables were combined into the table below and revealed the following:
<table>
<thead>
<tr>
<th></th>
<th>154 – 113 (US) (vs. Ciprofloxacin IV 400 bid→PO Ciprofloxacin 750 bid)</th>
<th>154 – 137 (Europe) (vs. Ceftazidime 2 gm IV bid→PO Ciprofloxacin 750 bid)</th>
<th>Combined Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. Cured/No. Eval (%)</td>
<td>No. Cured/No. Eval (%)</td>
<td>No. Cured/No. Eval (%)</td>
</tr>
<tr>
<td>Trovan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monotherapy</td>
<td>28/46</td>
<td>61</td>
<td>33/54</td>
</tr>
<tr>
<td>Adjunctive</td>
<td>7/10</td>
<td>70</td>
<td>1/7</td>
</tr>
<tr>
<td>Both</td>
<td>35/56</td>
<td>63</td>
<td>34/61</td>
</tr>
<tr>
<td>Comparator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monotherapy</td>
<td>32/48</td>
<td>67</td>
<td>33/53</td>
</tr>
<tr>
<td>Adjunctive</td>
<td>4/9</td>
<td>44</td>
<td>2/12</td>
</tr>
<tr>
<td>Both</td>
<td>36/57</td>
<td>63</td>
<td>35/65</td>
</tr>
</tbody>
</table>

95% CI with CCF (d = 20)

Study 154 – 113:
Trovan Monotherapy vs. Ciprofloxacin Monotherapy: - 27%, 15.7%
Trovan Both vs. Ciprofloxacin Both: - 20.2%, 19%

Study 154 – 137:
Trovan Monotherapy vs. Ceftazidime/Ciprofloxacin Monotherapy: - 21.4%, 19%
Trovan Both vs. Ceftazidime/Ciprofloxacin Both: - 17.1%, 21%

Combined:
Trovan Monotherapy vs. Comparators Monotherapy: - 18%, 11%
Trovan Both vs. Comparators Both: - 12.5%, 14%

The MO requested that the sponsor provide line listings of the patients included in the adjunctive categories in the above table. These were faxed on December 11, 1997 and revealed the following:

In study 113: 7/10 (70%) trovafloxacin patients received aztreonam (2 failures, 5 cured or improved), 4/10 (40%) trovafloxacin patients received vancomycin (1 failure, 3 cured or improved), and none of the trovafloxacin patients received adjunctive anaerobic coverage. Only 1 of these patients received both vancomycin and aztreonam and that patient was improved at the EOS.

On the ciprofloxacin arm, only 1/9 (11%) patients received aztreonam and was a failure. This patient also received clindamycin. 2/9 (22%) patients received vancomycin and both were failures. One of those patients also received clindamycin. 6/9 (66%) patients received clindamycin and in addition to the 2 aforementioned failures, 2/6 were failures (or 4 total failures) and 2/6 (22%) were cured.

In study 137: 4/7 (57%) trovafloxacin patients received gentamicin (3 failures and 1 cured), 4/7 (57%) received vancomycin (all failed), and no patient received additional anaerobic coverage. Only one of these patients received both gentamicin and vancomycin and was a failure.

On the ceftazidime/ciprofloxacin arm, 8/12 (67%) patients received gentamicin (6 failures and 2 cured), 6/12 (50%) received vancomycin (5 failures and 1 cured), and none of the patients received additional anaerobic coverage. There were 2 patients who received both gentamicin and vancomycin (1 failure and 1 cured).

**Medical Officer's Comment:** Very similar numbers of patients from both studies combined received monotherapy versus concomitant therapy. Interestingly, only 1 (11%) patient on the ciprofloxacin arm of study 113 received additional anaerobic coverage as opposed to 7 or 70% of the trovafloxacin patients. The main difference in study 113 was the addition of anaerobic coverage in 67% of the ciprofloxacin patients and none of the trovafloxacin patients. However, in study 154 – 137, none of the
severely ill patients on either arm received anaerobic coverage. Similar numbers of patients on both arms received gentamicin and vancomycin.

The 95% CI for the monotherapy patients in study 154–113 with severe NP indicated that trovafloxacin was NOT equivalent to ciprofloxacin. Additionally, equivalence was not demonstrated when all severe trovafloxacin patients, any mode of therapy were compared to all severe ciprofloxacin patients, any mode of therapy. Equivalence was also not demonstrated for monotherapy in study 154–137. In both studies combined, trovafloxacin monotherapy was equivalent to comparators monotherapy. Equivalence was also demonstrated in trovafloxacin patients with severe disease, combination therapy versus ceftriaxone/ciprofloxacin combination therapy in study 154–137, as well as in both studies combined.

Initially it appeared as if there was some superiority of trovafloxacin adjunctive therapy in both studies versus the adjunctive therapy comparators both studies, that is 47% versus 29%. However the numbers are too small 7/18 versus 6/21 to be able to detect any real difference.

From the above, the MO was unable to detect any superiority of trovafloxacin monotherapy versus comparators either as monotherapy or in conjunction with adjunctive antimicrobial therapy. Indeed, equivalence was not shown between trovafloxacin monotherapy and ciprofloxacin monotherapy in the pivotal US study or the open European study for severe NP. However, when the studies were combined, equivalence was demonstrated.

The above table was emailed to the sponsor on 12/10/97 for further comment with regards to trovafloxacin’s claim of superiority as a monotherapeutic agent versus ciprofloxacin in the treatment of severe (as defined by ATS criteria) nosocomial pneumonia.

Medical Officer’s Conclusion: The sponsor was unable to adequately demonstrate that trovafloxacin monotherapy was superior to ciprofloxacin monotherapy or combination therapy or both combined in the severely ill (as defined by ATS criteria) population. Trovafloxacin combination therapy was equivalent with the comparators combination therapy in study 154–137 and with all studies combined but not equivalent with ciprofloxacin combination in the pivotal US study.

The question of the adequacy of the comparator regimen becomes moot in the face of these analyses. If trovafloxacin was unable to meet the 95% CI at a lower than approved dose of ciprofloxacin for severe NP, then the issue of the use of the appropriate dose raises questions as to the efficacy of trovafloxacin for the indication itself.

Based on the above, the MO does not recommend approval for trovafloxacin in patients with severe nosocomial pneumonia.

On, December 12, 1997, the sponsor submitted a document entitled “Further Comments on Inclusion of Staphylococcus aureus and Klebsiella Pneumoniae in Nosocomial Pneumonia and Community Acquired Pneumonia Indications” in which the sponsor presented further arguments as to why Staphylococcus aureus and Klebsiella pneumoniae are legitimate organisms for both of these indications and that sufficient data are available to include them. Portions of the sponsor’s arguments are appended below:

Staphylococcus aureus:

—In Nosocomial pneumonia alone, there were 21 Staphylococcus aureus isolated and 14 successfully clinically treated at EOS (67%) in the two trovafloxacin protocols, results equal to the overall outcomes. The figures for the comparators are 10/21 (48%). The somewhat better efficacy with trovafloxacin is not surprising since trovafloxacin is at least an order of magnitude more active than ciprofloxacin or ceftriaxone. In CAP, 18/18 were successfully treated in the trovafloxacin arms.

—Staphylococcus aureus was included in the levofloxacin CAP indication, apparently on the basis of successful outcomes in 15/17 cases, as reported in the clinical trials section of the package.
insert. As noted below however, the levofloxacin CAP studies were very weak in key design areas (one was unblinded and the other non-comparative).

---Staphylococcus aureus was included in the recent Zosyn® label for Nosocomial pneumonia apparently on the sole basis of organisms acquired in the single pivotal trial vs. cefazidime in which 155 patients were randomized to Zosyn®. From the medical officer's review (p. 75), it is apparent that approval was gained on the basis of 13 successful courses out of 16 isolates.

---We regard this as a 'level playing field' issue. We believe we have studied adequate numbers that are at least equal to those studied in recent approvals. We do not believe the sponsors of levofloxacin and Zosyn® were required to specially 'prove the validity' of this particular isolate as Pfizer was, for an organism that is generally regarded as a pathogen in these infections.

**Medical Officer's Comment:** The MO determined that the information presented above refers to 2 different indications, that is NP and CAP. With regards to NP, the MO found a combined clinical response rate of 12/19 (63%). The MO's rate is slightly lower than that of the sponsor, however, this rate is superior to that found in the ciprofloxacin NDA 19-847/5-3 for severe NP: 8/14 (57%). As noted previously, ciprofloxacin did not obtain an approval for this isolate in severe disease.

With regards to the Zosyn® NDA 50-684, the MO noted previously, that an approval was granted based on an eradication rate (EOS) of 13/16 (81%).

The MO determined that the levofloxacin data for the CAP indication are not pertinent to the current indication. A previous divisional decision stated that it would be inappropriate to extrapolate data form a more severe indication to a lesser severe.

Nevertheless, the MO agreed with the sponsor with regards to the adequacy of the data presented in the trovafloxacin submission. Certainly, this submission contained adequate information to grant an approval for this isolate in patients with mild to moderate NP only. The MO clarifies this issue because the data from the Zosyn® NDA, despite being obtained from a single clinical trial, were obtained from a severely ill population and the cure rate was higher than that of trovafloxacin. Additionally, as per the MO's data, the comparators in the ciprofloxacin NDA 19-847/5-3 had a combined clinical response rate of 10/15 (67%).

As per the sponsor:

**Klebsiella pneumoniae**

---Across nosocomial pneumonia and CAP, 18/24 Klebsiella pneumoniae isolates were successfully treated. Eight were from Nosocomial pneumonia with 4 clinical successes, while 16 were from double blind, randomized, controlled trials in CAP, with 14/16 successfully treated (EOS). From p. 407 of the medical officer's review of levofloxacin, it appears that there were only 6 clinically evaluable subjects with this isolate, several of which appear to have originated in the non-comparative trial #M92-075. The medical officer did not recommend approval for this organism, however, there is a reference on p. 427 to additional data from supportive trials in an 'addendum', which is not available to Pfizer.

---The only other recent reference to Klebsiella pneumoniae is the levofloxacin package insert clinical trials section, where a figure of 10 isolates, all successfully treated, is cited.

---We regard this as a 'level playing field' issue. The primary source of the Klebsiella pneumoniae for the levofloxacin label was from an unblinded study (vs. ceftriaxone/cefuroxime) which was justly criticized by the medical officer because of this and other deficiencies. The only further data seem to have come from a non-comparative study, as reported in the clinical trials section. The trovafloxacin CAP data on Klebsiella pneumoniae are from much more robust double blind studies. More Klebsiella pneumoniae were studied in the trovafloxacin CAP program, by a considerable margin than in the levofloxacin program.
--The agency may fairly take the position that it has made an egregious error in the levofloxacin label and will not include organisms on such flimsy data in the future. However, the trovafloxacin data are much more robust and much greater in quantity. To not include Klebsiella pneumoniae would be unfair.

**Medical Officer's Comment:** As per the MO and the sponsor the clinical response rate by pathogen for Klebsiella pneumoniae was 4/8 (50%). Both studies combined in NP. The MO determined that this rate was very low compared with that of ciprofloxacin in NDA 19 - 847/S-3: 8/9 (89%). The MO, as noted above, determined in conjunction with the Division, that it would be inappropriate to extrapolate data from a less severe indication (CAP), to a more severe (NP).

Based on the above, the MO continues to recommend a non-approval for this organism in NP.

**Medical Officer's Overall Conclusion:**

Based on all the data reviewed and after labeling discussions with the sponsor on 12/18/97, the MO agreed to recommend approval for trovafloxacin in the treatment of NP without referring to severity. This decision was made because of the equivalent efficacy between trovafloxacin and the comparator agents in both clinical trials for the overall populations. The sponsor agreed to a Phase 4 commitment.

**Recommended Regulatory Action:**

The following statement should be added to the Indications and Usage section of the labeling:

Additionally, this statement should be added to the Dosage and Administration section. The approved dose is alatrofloxacin/trovafloxacin 300 mg IV to 200 mg PO daily for 10-14 days.

A clinical studies section describing the results of the US trial is recommended.

---

Orig. NDA #20-759
Orig. NDA #20-760
HFD-590
HFD-590/Div. Dir./M.Goldberger
HFD-590/Dep. Dir./R.Alvissana
HFD-590/MTL/B.L.issani
HFD-590/MO/R.Alvissnata
HFD-590/CSO/P.Fogarty
HFD-725/Biostat/Sillisman
HFD-344/Thomas

/MS/ 2/1997
Regina Alvissatos, MD
Medical Officer, DSPIDP
### Appendix I/NDA 20 – 759

#### List of Investigators and Study Sites (Copied from the Esb):

**Uncomplicated UTI/154-103:**

<table>
<thead>
<tr>
<th>PRINCIPAL INVESTIGATORS</th>
<th>SUB-INVESTIGATORS</th>
<th>STUDY SITES</th>
</tr>
</thead>
<tbody>
<tr>
<td>5003 James McCarty, MD.</td>
<td>Richard Assolli, MD</td>
<td>California Medical Research Group</td>
</tr>
<tr>
<td></td>
<td>Katherine Baker, RA</td>
<td>3636 North First Suite 120</td>
</tr>
<tr>
<td></td>
<td>R. Wayne Ball, MD</td>
<td>Fresno Ca 93726</td>
</tr>
<tr>
<td></td>
<td>Andrea Braungiger, MD</td>
<td>Cal Poly State University</td>
</tr>
<tr>
<td></td>
<td>Burt Cochran, MD</td>
<td>Cal Poly Health Services</td>
</tr>
<tr>
<td></td>
<td>Joann Crawford, RN</td>
<td>San Luis Obispo, Ca</td>
</tr>
<tr>
<td></td>
<td>Diane Dubose, MA</td>
<td>53407</td>
</tr>
<tr>
<td></td>
<td>Barbara Fragale, RN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M. Gall Gallagher, HP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cathy Good, RN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Karen Heesch, RN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yvette Hemon, RN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeanne Kokes, RN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Margaret Northrop, RN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Juan Patlan, PA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Josie Regalado, MA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antonio Renteria, RN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gloria Rodriguez, MA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sharon Zarcone, LPN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Terese Crockett, RN</td>
<td></td>
</tr>
<tr>
<td>5005 Willis Manford Gooch, III, MD.</td>
<td>Daniel Davis, MD</td>
<td>Medical Research Associates Of Utah Incorporated</td>
</tr>
<tr>
<td></td>
<td>John Hermod, MD</td>
<td>265 East 100 South, Suite 255</td>
</tr>
<tr>
<td></td>
<td>Spencer Jones, MD</td>
<td>Salt Lake City, Ut 84111</td>
</tr>
<tr>
<td></td>
<td>Tina Kerr, LPN</td>
<td>Bryner Clinic</td>
</tr>
<tr>
<td></td>
<td>Darla Longhurst, MD</td>
<td>745 East 300 South</td>
</tr>
<tr>
<td></td>
<td>Rodney Marotti, MD</td>
<td>Salt Lake City, Ut 84102</td>
</tr>
<tr>
<td></td>
<td>Kenneth Nielson, MD</td>
<td>St. Benedict's Women's Center, 5495 South 500</td>
</tr>
<tr>
<td></td>
<td>Cheryl Ritchie, RN</td>
<td>East Washington Terrace, Ut 84405</td>
</tr>
<tr>
<td></td>
<td>Mark Shepherd, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Larry Staker, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jennifer Tower</td>
<td></td>
</tr>
<tr>
<td>5006 Corey Tancik, MD</td>
<td>Barbara McGuire, MD</td>
<td>New Mexico Medical Group 8324 Constitution Place Northeast</td>
</tr>
<tr>
<td></td>
<td>William Mitchell, MD</td>
<td>Albuquerque, NM 87110</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Sollins, MD</td>
<td>Kiva-New Mexico Medical Group Po-2, 8324 Constitution Place Northeast</td>
</tr>
<tr>
<td></td>
<td>Lori Spragg, MA</td>
<td>Albuquerque, NM 87110</td>
</tr>
<tr>
<td></td>
<td>David Stryker, MD</td>
<td>Future Healthcare Research Center 975</td>
</tr>
<tr>
<td></td>
<td>Barbara Wright, RN</td>
<td>Johnson Ferry Road Suite 370</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atlanta, GA 30342</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atlanta Northside Center For Women 880 Johnson Ferry Road Suite 350, Atlanta, GA 30342</td>
</tr>
</tbody>
</table>

**Appears this way on original**

**Appears this way on original**
Joseph Geleski, III, MD
Katherine Smallwood, MD
Neshan Vranian, MD
Carol Carill, RN
Ruth Donahue, MD
Catharine Moffett, RN
Diane Morgenthaler, MD
Robert Cheull, MD
David Getz, MD
Bruce Karlin, MD
Mark Lemons, MD

The McGuire Clinic Incorporated
7702 Parham Road
Richmond, VA 23229

Women's Care Medical Center 85
Pogeaganut Road Groton Business
Park Route 117
Groton, CT 06340

5 Water Street
Milford, MA 01757;
270 High Street
Clinton, MA 01510

Virginia Abu Dalu, RN

Gary Blumberg, DO
Aleyda Boruge, MD

100 North Euclid Suite 710
St Louis, MO 63108

University Clinical Research
1150 North University Drive
Pembroke Pines, FL 33024

Urology Center Of Florida
3201 Southwest 34th Street
Ocala, FL 34474

James Antinori, M.D.
Kathy Atkinson, MD
Daniel Duggleby, MD
Robert Gannon, MD
Lance Owens, MD
Marita Frather, MD
Michael Rommey, MD

1388 Arlington Drive
Salt Lake City, UT 84103

Holy Cross Hospital
1050 East South Temple
Salt Lake City, UT 84102

Daniel Austin, MD
Carole Christensen, MD
Peter Earl, MD
John Imig, MD
Marlene Kaniuk, MD
Sherbune Macfarlan, MD

Boulder Medical Center Research
Department
2750 Broadway
Boulder, CO 80304

Julian Fuentes, MD

Southern California Research
Institute
12291 East Washington Boulevard
Suite 204
Whittier, CA 90606

R/D Clinical Research Incorporated
135 Oyster Creek Drive Suite V
Lake Jackson, TX 77566

University Of Kentucky College
Of Pharmacy Rose Street
Room 318
Lexington, KY 40536-0082
University Of Kentucky
Medical Center 800 Rose Street
Lexington KY 40536;
Veterans Administration Hospital
Cooper Drive
Lexington, KY 40511

3550 Lutheran Parkway West Suite
G-20
Wheat Ridge, Co 80033

Sara O'Heron, MD
Harvey Resnick, MD
Irvin Sabrutsa, MD
Nomran Goodman, Ph.D
Susan Griffith, MD
Larry Munch, MD
David Wood, MD

Lawrence Repsher, MD

Robert Bedinger, Jr, MD
Caryn Nesbitt, MD.
Anthony Puopolo, MD.
Z.A. Dalu, MD
Larry Glederman, DO.
Ira Klimberg, MD
John Gezon, MD.
Theodore Appel, MD
Robert Fiddes, MD
Joseph Scott, MD
Daniel Wermeling, Pharm. D.
Charles Jenkins, MD
<table>
<thead>
<tr>
<th>PRINCIPAL INVESTIGATORS</th>
<th>SUBINVESTIGATORS</th>
<th>STUDY SITES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jose Ibarra, M.D.</td>
<td>Ariya Abraham, M.D.</td>
<td>Future Healthcare Research Center</td>
</tr>
<tr>
<td>James McCarty, M.D.</td>
<td>Richard Ascoli, M.D.</td>
<td>3636 North First Street #120</td>
</tr>
<tr>
<td></td>
<td>R. Wayne Ball, M.D.</td>
<td>Fresno, CA 93726</td>
</tr>
<tr>
<td></td>
<td>Nancy Biele, M.D.</td>
<td>California Poly Technic State University</td>
</tr>
<tr>
<td></td>
<td>Hani Boutros, M.D.</td>
<td>Student Health Services</td>
</tr>
<tr>
<td></td>
<td>Andrea Brauninger, M.D.</td>
<td>San Luis Obispo, CA 93407</td>
</tr>
<tr>
<td></td>
<td>Julian Carabeth, M.D.</td>
<td>San Luis Obispo Family Practice</td>
</tr>
<tr>
<td></td>
<td>Burt Cochran, M.D.</td>
<td>47 Santa Rosa</td>
</tr>
<tr>
<td></td>
<td>Frank Mazzone, M.D.</td>
<td>San Luis Obispo, CA 93405</td>
</tr>
<tr>
<td></td>
<td>Anthony Molina, M.D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Juan Pefian, P.A.-C.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thomas Richards, M.D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parimal Shah, M.D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anila Thampy, M.D.</td>
<td></td>
</tr>
<tr>
<td>Willis Gooch, III, M.D.</td>
<td>Daniel Davis, M.D.</td>
<td>Medical Research Associates of Utah, Inc.</td>
</tr>
<tr>
<td></td>
<td>John Herrod, M.D.</td>
<td>265 East 100 South, Suite 255</td>
</tr>
<tr>
<td></td>
<td>Ann Jefferds, M.D.</td>
<td>Salt Lake City, UT 84111</td>
</tr>
<tr>
<td></td>
<td>Spencer Jones, M.D.</td>
<td>Bryner Clinic</td>
</tr>
<tr>
<td></td>
<td>Kenneth Nielsen, M.D.</td>
<td>745 E. 300 South</td>
</tr>
<tr>
<td></td>
<td>Keith Pearson, M.D.</td>
<td>Salt Lake City, UT 84102</td>
</tr>
<tr>
<td></td>
<td>Dorene Sambado, M.D.</td>
<td>Umap Clinic</td>
</tr>
<tr>
<td></td>
<td>Mark Shepherd, M.D.</td>
<td>250 E. 300 S. 200</td>
</tr>
<tr>
<td></td>
<td>John Smith, M.D.</td>
<td>Salt Lake City, UT 84111</td>
</tr>
<tr>
<td></td>
<td>Lorraine Szczesny, M.D.</td>
<td></td>
</tr>
<tr>
<td>Anthony Puopolo, M.D.</td>
<td>Aly El-Hag, M.D.</td>
<td>Medical Associates of Salt Lake</td>
</tr>
<tr>
<td></td>
<td></td>
<td>508 E. S. Temple, Suite 300</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Salt Lake City, UT 84102</td>
</tr>
<tr>
<td>Larry Glderman, D.O.</td>
<td>Aleyda Borge, M.D.</td>
<td>5 Water Street</td>
</tr>
<tr>
<td></td>
<td>Jose Molina, P.A.</td>
<td>Milford, MA 01757</td>
</tr>
<tr>
<td>Robert Fiddes, M.D.</td>
<td>Peter Arcan, M.D.</td>
<td>1150 North University Drive</td>
</tr>
<tr>
<td></td>
<td>Julien Fuentes, M.D.</td>
<td>Pembroke Pines, FL 33024</td>
</tr>
<tr>
<td>Randall Stoltz, M.D.</td>
<td>Patrick Flamion, M.D.</td>
<td>12291 East Washington Blvd.</td>
</tr>
<tr>
<td></td>
<td>Bryan Laura, M.D.</td>
<td>Whittier, CA 90606</td>
</tr>
<tr>
<td></td>
<td>Richard Murray, M.D.</td>
<td>GFI Pharmaceutical Services Inc.</td>
</tr>
<tr>
<td></td>
<td>Ward Neff, M.D.</td>
<td>800 St. Mary’s Drive</td>
</tr>
<tr>
<td></td>
<td>Raymond Newnum, M.D.</td>
<td>Evansville, IN 47714</td>
</tr>
<tr>
<td></td>
<td>John Polin, M.D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jennifer Wahle, M.D.</td>
<td></td>
</tr>
<tr>
<td>Hendrik Mulder, M.D.</td>
<td>Jacobus Koster, M.D.</td>
<td>Medisch Onderzoekscentrum</td>
</tr>
<tr>
<td></td>
<td>Lennie Van Setten Van Der Meer, R.N.</td>
<td>Gcp Groot Hertoginnelaan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>34 N1-2517 Eh Den Haag</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Netherlands</td>
</tr>
</tbody>
</table>
Aikesh Amin, M.D.
Donald Bennett, M.D.
Gerald Bottenfield, M.D.
Raymond Jess, M.D.
Sara O'Teron, M.D.
Ronald Paul, M.D.
Harvey Resnick, M.D.
Irvin Sbrinula, M.D.
Joseph Scott, M.D.
Roberto Ticas, M.D.

R/D Clinical Research Inc.
135 Oyster Creek Drive
Suite W, Suite V, Suite S
Lake Jackson, TX 77566

201 Oak Dr. South, Suite 107
Lake Jackson, TX 77566

201 Oak Dr. South, Suite 202
Lake Jackson, TX 77566

215 Oak Dr. South, Suite A
Lake Jackson, TX 77566

56 Flag Lake Plaza
Lake Jackson, TX 77566

201 Oak Dr. South, Suite 203
Lake Jackson, TX 77566

146 Hospital Drive, Suite 102
Angleton, TX 77515

215 Oak Dr. South, Suite B
Lake Jackson, TX 77566

James Borden, M.D.
Paul Bretton, M.D.
William Evans, M.D.
Ronice Kluge, M.D.
Sergio Mather, M.D.
David Mitchie, Ph.D.
Jasper Rizzo, M.D.
Mary Yankaskas, M.D.
Stephen Zellner, M.D.

12651 Whitehall Drive
Fort Myers, FL 33907

Clinical Physiology Associates
Clinical Study Center
4110 Center Pointe Drive, Suite 219
Fort Myers, FL 33916

Southwest Florida Urologic Associates
12651 Whitehall Drive
Fort Myers, FL 33907

Southwest Florida Urologic Associates
507 Del Prado Boulevard
Cape Coral, FL 33990

Gulfshore Obstetrics and Gynecology
12631 Whitehall Dr.
Fort Myers, FL 33907

Internal Medicine Associates
2675 Winkler Ave., Suite 300
Fort Myers, FL 33901
5632
Ronald Gove, M.D.

Peter Costantini, D.O.
Alan Feldman, M.D.

Jersey Research Foundation Inc.
1001 North Main St.
Pleasantville, NJ 08232
Jersey Research Foundation, Inc.
222 New Road
Linwood, NJ 08221

Jersey Research Foundation, Inc.
53 West White Horse Pike
Absecon, NJ 08205

5633
Gholam Malek, M.D.

Percy Golson
Andrew Graf, M.D.
Michael Kuglitsch, M.D.
John Mahler, M.D.
John Wegenke, M.D.

Jackson Foundation Physicians Plus
345 West Washington Ave.
Madison, WI 53703
Physicians Plus Medical Group
20 South Park St.
Madison, WI 53715

2222 State Street, Suite D
Nashville, TN 37203

Clinical Research Associates, Inc.
2222 State Street, Suite D
Nashville, TN 37203

2400 Patterson Street, Suite 204
Nashville, TN 37203

Urology Associates
211 Church St., Suite 600
Nashville, TN 37203

2021 Church St.
Nashville, TN 37203

711 Lawn Ave., Building 1
Sellersville, PA 18960

Grand View Hospital
700 Lawn Ave.
Sellersville, PA 18960

Pennridge Urological Associates
670 Lawn Ave.
Sellersville, PA 18960

Infections Limited PS
1624 South 1 Street 402
Tacoma, WA 98405

5635
Marcia Montgomery, M.D.

Bryan R. Kurtz, M.D.
Raoul Concepcion, M.D.
Cynthia Lee Shearer, M.D.

5636
Stuart Sarnik, M.D.

5637
Alan Tice, M.D.

Philip Craven, M.D.
Peter Marsh, M.D.
David McEnty, M.D.
Lawrence Schwartz, M.D.
Catherine Treseler, M.D.

APPEARS THIS WAY ON ORIGINAL

APPEARS THIS WAY ON ORIGINAL
5681
Abdollah Irvani, M.D.

John Langton, M.D.

Central Florida Medical Research Center
1720 South Orange Ave., Suite 401
Orlando, FL 32806

University of Central Florida (UCF)
UCF Student Health Services
400 Central Florida Blvd., Bldg. 27
Orlando, FL 32816

5733
Ellen Guthrie, M.D.

John Corkery, M.D.
John Crites, M.D.
Margaret Cronin, M.D.
Bessann Dawson, M.D.
Franziska Garrett, M.D.
Deepa Gupta, M.D.
Dennis Kay, M.D.
Gary McFadden, M.D.
Adrian Milea, M.D.
Karen Neal, D.O.
Mark Passey, M.D.
Leonard Portocarrero, M.D.
Drew Schembre, M.D.
Kathleen Tucker, M.D.
Alan Whitesides, M.D.

Advanced Clinical Research
34 South 500 East 102
Salt Lake City, UT 84102

Rose Park Insta Care
55 North Redwood Rd.
Salt Lake City, UT 84116

Bountiful Insta Care
214 West 1500 South
Bountiful, UT 84010

Holladay Insta Care
3934 South 2300 East
Salt Lake City, UT 84124

Sugar House Insta Care
2915 South 700 East
Salt Lake City, UT 84106

5783
Philippe Angell, M.D.

5784
Marc Hindamian, M.D.

5785
Max Labyod, M.D.

5786
Jacques Sultan, M.D.

Toledano, M.D.

Groupe Medical De La Mairie
5 Place De L'Eglise
84260 Fresnes
France

5787
Sylvaine Dumas, M.D.

5790
Gosta Granberg, M.D.

Manochehr Nezami

Kvinnoklinikken Centralasarette I
Boden S-961
85 Boden
Sweden

Kvinnoklinikken Lulea
Laresett 971
25 Lulea
Sweden
<table>
<thead>
<tr>
<th>5791</th>
<th>Elisabeth Weiner, M.D.</th>
<th>Ann-Marie Terner, M.D.</th>
<th>Brickegardens Vardcentral Osterleden 10 S-691 81 Karlshoga Sweden</th>
</tr>
</thead>
<tbody>
<tr>
<td>5792</td>
<td>Anders Henriksson, M.D.</td>
<td>Inger Aurell, M.D.</td>
<td>Specialistiaarhuset Harnelinen Box 195 S-971 06 Lulea Sweden</td>
</tr>
<tr>
<td>5793</td>
<td>Leif Weiner, M.D.</td>
<td>Agneta Moller, M.D.</td>
<td>Medicinliniken Karlshoga Lassret S-691 81 Karlshoga Sweden</td>
</tr>
<tr>
<td>5794</td>
<td>Bengt Widgren, M.D.</td>
<td>Bengt Persson, M.D.</td>
<td>Department of Medicine Sahlgrenska Sjukhuset S-413 45 Goteborg Sweden</td>
</tr>
<tr>
<td>5797</td>
<td>Roland Weil, M.D.</td>
<td></td>
<td>Habichstr 10 75175 Pforzheim Germany</td>
</tr>
<tr>
<td>5798</td>
<td>Reinhard Schorten, M.D.</td>
<td></td>
<td>Schleibehimstr 77 85221 Dauchau Germany</td>
</tr>
<tr>
<td>5799</td>
<td>Christian Saul, M.D.</td>
<td></td>
<td>Nymphenburger Str 59 80335 Munchen Germany</td>
</tr>
<tr>
<td>5801</td>
<td>Jens Herold, M.D.</td>
<td></td>
<td>Leopoldstr 71 80802 Munchen Germany</td>
</tr>
<tr>
<td>5802</td>
<td>Constantin Aurel Baran, M.D.</td>
<td></td>
<td>Troppenauerstr 6c 85221 Dauchau Germany</td>
</tr>
<tr>
<td>5803</td>
<td>Hendrik Mulder, M.D.</td>
<td>H. Christiaanse Pauline De Graaf-Pernot Mrs. Edolus Pietemella Van Wendel De Joode</td>
<td>Medisch Onderzoekscentrum Gcp Weiiburgerweg 33 N1-3039 Ac Rotterdam The Netherlands</td>
</tr>
<tr>
<td>5804</td>
<td>Hans Prak, M.D.</td>
<td>Bernardina Prak-Holtzing</td>
<td>Medisch Onderzoekscentrum Gcp Bergweg 66 N1-3036 Bc Rotterdam The Netherlands</td>
</tr>
<tr>
<td>5821</td>
<td>Harry Fransen, M.D.</td>
<td>A. Oost-Buurman</td>
<td>Rembrandtslaan3 N1-9581 Aj Musselkanaal The Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Markstraat 70 N1-9581 Ad Musselkanaal The Netherlands</td>
</tr>
</tbody>
</table>
**Study 154 –117/Complicated UTI:**

<table>
<thead>
<tr>
<th>PRINCIPAL INVESTIGATORS</th>
<th>SUBINVESTIGATORS</th>
<th>STUDY SITES</th>
</tr>
</thead>
<tbody>
<tr>
<td>5005 Willis Gooch III, MD</td>
<td>Daniel Davis, MD</td>
<td>Medical Research Associates of Utah, Inc.</td>
</tr>
<tr>
<td></td>
<td>John Herrod, MD</td>
<td>265 E. 100 South</td>
</tr>
<tr>
<td></td>
<td>Ann Jeffers, MD</td>
<td>Suite 255</td>
</tr>
<tr>
<td></td>
<td>Spencer Jones, MD</td>
<td>Salt Lake City, UT 84111</td>
</tr>
<tr>
<td></td>
<td>Kenneth Nielson, MD</td>
<td>Bryner Clinic</td>
</tr>
<tr>
<td></td>
<td>Keith Pearson, MD</td>
<td>745 E. 300 South</td>
</tr>
<tr>
<td></td>
<td>Dorene Sambado, MD</td>
<td>Salt Lake City, UT 84102</td>
</tr>
<tr>
<td></td>
<td>Mark Shepherd, MD</td>
<td>UMAP Clinic</td>
</tr>
<tr>
<td></td>
<td>John Smith, MD</td>
<td>250 E. 300 South</td>
</tr>
<tr>
<td></td>
<td>Lorraine Szczesny, MD</td>
<td>Suite 200</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Salt Lake City UT 84111</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical Associates of Salt Lake</td>
</tr>
<tr>
<td></td>
<td></td>
<td>508 E. S. Temple</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suite 300</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Salt Lake City UT 84102</td>
</tr>
<tr>
<td>5034 Guillermo Rodriquez, MD</td>
<td>Celia Barrantes Howay, MD</td>
<td>Hospital Mexico</td>
</tr>
<tr>
<td></td>
<td>Katy Barrantes Jimenez, MD</td>
<td>3er Piso Biblioteca Medica</td>
</tr>
<tr>
<td></td>
<td>Andrea Bianchi, MD</td>
<td>San Jose</td>
</tr>
<tr>
<td></td>
<td>Sofia Gonzalez Ugalde, MD</td>
<td>Costa Rica</td>
</tr>
<tr>
<td></td>
<td>Jorge Mora Duarte, MD</td>
<td>Hospital Calderon Guardia</td>
</tr>
<tr>
<td></td>
<td>Iris Perez Quiros, MD</td>
<td>PO Box 10105</td>
</tr>
<tr>
<td></td>
<td></td>
<td>San Jose, Costa Rica</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital San Juan De Dios</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO Box 10105</td>
</tr>
<tr>
<td></td>
<td></td>
<td>San Jose, Costa Rica</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Centro Nacional De Rehabilitacion (Cenare)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO Box 10105</td>
</tr>
<tr>
<td></td>
<td></td>
<td>San Jose, Costa Rica</td>
</tr>
<tr>
<td>5078 C. Andrew Deabate, MD</td>
<td>Victor Brown, MD</td>
<td>Medical Research Center</td>
</tr>
<tr>
<td></td>
<td>J. Craig Cornett, MD</td>
<td>1020 Gravier Street</td>
</tr>
<tr>
<td></td>
<td></td>
<td>New Orleans, LA 70112</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3600 Prytania St.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suite 100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>New Orleans, LA 70115</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical Research Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3655 Veteran’s Boulevard</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metairie, LA 70002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1020 Gravier St.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>New Orleans, LA 70112</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Waiden Healthcare Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2401 Idaho</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kenner, LA 70062</td>
</tr>
</tbody>
</table>
5138
Randall Stoltz, MD
Patrick Flamion, MD
Bryan Laura, MD
Richard Murray, MD
Ward Neff, MD
Raymond Newnum, MD
John Polin, MD
Jennifer Wahle, MD

5606
Robert Gainer, MD
T. Edward Blume, MD
Robert Curtis, MD
Suzanne Gainer
Alan Hess, MD
Timothy Helms, MD
Novel Rasussen, MD
Jeffrey Sinclair, MD

5639
Stephen Auerbach, MD
Ronald Gilbert, MD
Richard Holevas, MD
John Ravera, MD
Joel Sheiner, MD
Ronald Solomon, MD
Don Udall, MD

5640
Bruce Blank, MD
Jack Brewer, MD
Romney Burke, MD
Jerry Glesy, MD
Michael Kaempf, MD
Theodore Lehman, MD
Gregory McCoy, MD
Patrick Ollila, MD
Walter Reynolds, MD
David Winchester, MD

GFI Pharmaceutical Services, Inc.
800 St. Mary's Drive
Evansville, IN 47714

Morgantown Internal Medicine Group, Inc.
300 Wedgewood Dr.
Morgantown, WV 26505

Monongalia General Hospital
1200 JD Anderson Dr.
Morgantown, WV 26505

400 Newport Center Dr.
Suite 301
Newport Beach, CA 92660

1401 Avocado Ave.
Suite 608
Newport Beach, CA 92660

1901 Westcliff Dr.
Suite 2
Newport Beach, CA 92660

16912 Sims St.
Suite 203
Huntington Beach, CA 92649

351 Hospital Dr.
Suite 516
Newport Beach, CA 92663

1401 Avocado Ave.
Suite 602
Newport Beach, CA 92660

Urology Clinic PC
1130 Northwest 22nd Ave.
Suite 620
Portland OR 97210

The Urology Clinic
501 N. Graham
Suite 420
Portland, OR 97227

1400 Division St.
Suite 1
Oregon City, OR 90745
5641
Howard Rottenberg, MD
James Brigman, MD
Douglas Nyhoff, MD
Harvey Tauber, MD
North Atlanta Urology Associates PC
5671 Peachtree
Dunwoody Road
Suite 300
Atlanta GA 30342
Nucare Clinical Trials, Inc.
3420 McClure Bridge Rd.
Duluth GA 30096
Santa Monica Urological Medical Group
1200 15th St.
Suite 1200
Santa Monica, CA 90404
Santa Monica Urological Medical Group
1200 15th St.
Suite 709
Santa Monica CA 90404
San Fernando Valley Urologic Associates
Medical Group Inc.
18370 Burbank Blvd.
Suite 407
Tarzana CA 91356
7345 Medical Center Dr.
Suite 300
West Hills CA 91307
Clinical Research Associates
2222 State St.
Suite D
Nashville TN 37203
Urology Associates
2011 Church St.
Suite 600
Nashville TN 37203
2400 Patterson St.
Suite 204
Nashville TN 37203
University of Tennessee
Dept. of Urology
956 Court Ave.
Room H-216
Memphis TN 38163
Urology Specialists PC
160 Robbins
Waterbury CT 06708
5642
Stanley Brosman, MD
Matteo Dinolfo, MD
Stuart Fisher, MD
Ian Gale, MD
David Leff, MD
Richard Leff, MD
Ronald Nudelman, MD
James Orecklin, MD
Robert Saffian, MD
Arthur Schapiro, MD
Richard Shapiro, MD
Leonard Skaid, MD
5644
Raoul Concepcion, MD
Jon Levine, MD
Marcia Montgomery, MD
Richard Pinson, MD
5645
Clair Cox, MD
Anthony Patterson, MD
5647
Robert Feldman, MD
Joseph Antoci, MD
Michael Flanagan, MD
Scott Kantor, MD
Paul Kraus, MD
5650
Frank Maggiacomo, DO
Roger Ferland, MD
Silver Lake Medical Center
287 Pocasset Ave.
Providence RI 02909
Elmhurst Extended Care
50 Maude St
Providence RI 02908
Cedar Crest Nursing Home
125 Soutave Ave.
Cranston RI 02921
Morgan Health Center
80 Morgan Ave.
Johnston, RI 02919
Southern Drug Research
1222 14th Ave. South
Suites 101, 200, 206
Birmingham AL 35205
Health South Medical Center
Extended Care Facility
1201 11th Ave. South
Birmingham AL 35205
11009 Montgomery Highway
Vestavia Hills AL 35216
Lakeshore Rehabilitation Hospital
3800 Ridge Dr.
Homewood AL 35209
3550 Cote-Des-Neiges
Suite 550
Montréal Quebec H3H 1V4
Canada
Montréal General Hospital
1550 Cedar Avenue
Montréal Quebec H3G 1A5
Canada
Clinical Research Consultant Group
3550 Cote-Des-Neiges
Suite 550
Montréal Quebec H3H 1V4
Raleigh Medical Group
3521 Haworth Dr.
Raleigh NC 27609
Capitol Urology
3901 Computer Dr.
Raleigh NC 27609

5651
Barry McLean, MD
Sadri Aysar, MD
Richard May, MD
Frank McArthur, MD
Michael Rosemore, DO
William White, PharmD

5652
Michael Laplante, MD
Bernice Pynn, MD

5653
John Rubino, MD
Robert Bilbro, MD
Gerald Blake, MD
Lisa Dejarnette, MD
William Dunlap, MD
Allan Eure, MD
Kenneth Leatherman, MD
Mark McClure, MD
558

Central Carolina Urology Associates
3320 Wake Forrest Road
Suite 100
Raleigh NC 27609

Mesaba Clinic
1814 14th Ave. East
Hibbing MN 55746

Northeast Indiana Urology
7900 W. Jefferson Blvd.
Suite 301
Fort Wayne IN 46804

Jackson Foundation/Physicians Plus
345 W. Washington Ave.
Madison WI 53703

Physicians Plus Medical Group
20 S. Park St.
Madison WI 53715

Doctors Urology Group
Clinical Research Foundation
23441 Madison St.
Suite 130
Terrance CA 90505

Western Clinical Research
23441 Madison St.
Suite 130
Terrance CA 90505

Future Healthcare Research Center
6210 75th St. West
Suite A-200
Tacoma WA 98467

St. Clare Hospital
11315 Bridgeport Way Southwest
Tacoma WA 98467

South Florida Medical Research
12900 Northeast 17th Ave.
Suite 301
North Miami, FL 33181

South Florida Medical Research
610 N. Flamingo Road
Pembroke Pines FL 33028

South Florida Medical Research
7150 W. 20th Ave.
Suite 610
Hialeah FL 33016

5654
Susan Rudberg, MD
Richard Moyer, MD
Jon Rudberg, MD

5657
Christopher Steidie, MD
John Brinkman, MD

5658
John Wegnie, MD
Percy Golson, PA
Andrew Graf, MD
Michael Kuglitsch, MD
John Mahler, MD
Gholam Malek, MD

5661
Norman Zinner, MD
Alec Koo, MD
Fredrick Wolk, MD

5679
Lance Kürregaard, MD
Shinobu Inoue
Penny Miller
J.H. Winemiller, MD

5734
Marc Gittleman, MD
Mark Christ, MD
Barbara Montford, MD
Lawrence Winton, MD

APPEARS THIS WAY
ON ORIGINAL
<table>
<thead>
<tr>
<th>ID</th>
<th>Name, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>5735</td>
<td>William Moseley, MD</td>
</tr>
<tr>
<td></td>
<td>D. Howard Lowe, MD</td>
</tr>
<tr>
<td></td>
<td>Marianne Rochester, MD</td>
</tr>
<tr>
<td></td>
<td>South Florida Medical Research</td>
</tr>
<tr>
<td></td>
<td>3700 Washington St.</td>
</tr>
<tr>
<td></td>
<td>Suite 204A</td>
</tr>
<tr>
<td></td>
<td>Hollywood FL 33021</td>
</tr>
<tr>
<td></td>
<td>San Diego Uro-Research</td>
</tr>
<tr>
<td></td>
<td>1901 Fourth Ave.</td>
</tr>
<tr>
<td></td>
<td>Suite 200</td>
</tr>
<tr>
<td></td>
<td>San Diego CA 92101</td>
</tr>
<tr>
<td>5736</td>
<td>Thomas Showen, MD</td>
</tr>
<tr>
<td></td>
<td>C. Jeff Beach, PA</td>
</tr>
<tr>
<td></td>
<td>David Cook, MD</td>
</tr>
<tr>
<td></td>
<td>D. Patrick Currie, MD</td>
</tr>
<tr>
<td></td>
<td>Andrew Griffin, MD</td>
</tr>
<tr>
<td></td>
<td>Oliver Hart III, MD</td>
</tr>
<tr>
<td></td>
<td>Oliver Hart Jr., MD</td>
</tr>
<tr>
<td></td>
<td>Frederick Howell, MD</td>
</tr>
<tr>
<td></td>
<td>Minnie Mercer</td>
</tr>
<tr>
<td></td>
<td>Charles Reid, MD</td>
</tr>
<tr>
<td></td>
<td>Alston Stubbs, MD</td>
</tr>
<tr>
<td></td>
<td>Peidmont Research Associates</td>
</tr>
<tr>
<td></td>
<td>1901 S. Hawthorne Rd.</td>
</tr>
<tr>
<td></td>
<td>Suite 306</td>
</tr>
<tr>
<td></td>
<td>Winston-Salem NC 27103</td>
</tr>
<tr>
<td>5737</td>
<td>Joel Kaufman, MD</td>
</tr>
<tr>
<td></td>
<td>William Maniatis, MD</td>
</tr>
<tr>
<td></td>
<td>Jonathan Seidlin, MD</td>
</tr>
<tr>
<td></td>
<td>Thomas Watts, MD</td>
</tr>
<tr>
<td></td>
<td>Maplewood Urological</td>
</tr>
<tr>
<td></td>
<td>1806 S. Hawthorne Rd.</td>
</tr>
<tr>
<td></td>
<td>Winston-Salem, NC 27103</td>
</tr>
<tr>
<td></td>
<td>Aurora Urology PC</td>
</tr>
<tr>
<td></td>
<td>1421 S. Potomac St.</td>
</tr>
<tr>
<td></td>
<td>Suite 120</td>
</tr>
<tr>
<td></td>
<td>Aurora CO 80012</td>
</tr>
<tr>
<td>5738</td>
<td>Jacob Rajfer, MD</td>
</tr>
<tr>
<td></td>
<td>Abraham Grinvald, MD</td>
</tr>
<tr>
<td></td>
<td>Harbor-University of California</td>
</tr>
<tr>
<td></td>
<td>Los Angeles Medical Center</td>
</tr>
<tr>
<td></td>
<td>100 W. Carson St.</td>
</tr>
<tr>
<td></td>
<td>Torrance CA 90502</td>
</tr>
<tr>
<td>5781</td>
<td>C. Gilberto Brito, MD</td>
</tr>
<tr>
<td></td>
<td>Luis Arguesco, MD</td>
</tr>
<tr>
<td></td>
<td>Robert Bailey, MD</td>
</tr>
<tr>
<td></td>
<td>Larry Bans, MD</td>
</tr>
<tr>
<td></td>
<td>William Bohnert, MD</td>
</tr>
<tr>
<td></td>
<td>Eric Zeldman, MD</td>
</tr>
<tr>
<td></td>
<td>Urology Associates LTD</td>
</tr>
<tr>
<td></td>
<td>202 E. Earl Dr. #360</td>
</tr>
<tr>
<td></td>
<td>Phoenix AZ 85012</td>
</tr>
<tr>
<td>6096</td>
<td>Paul Brower, MD</td>
</tr>
<tr>
<td></td>
<td>Steven Rudy, MD</td>
</tr>
<tr>
<td></td>
<td>J. Bradley Taylor, MD</td>
</tr>
<tr>
<td></td>
<td>Jay Young, MD</td>
</tr>
<tr>
<td></td>
<td>South Coast Urological Medical Group</td>
</tr>
<tr>
<td></td>
<td>31862 Coast Highway</td>
</tr>
<tr>
<td></td>
<td>Suite 302</td>
</tr>
<tr>
<td></td>
<td>South Laguna CA 92677</td>
</tr>
<tr>
<td></td>
<td>South Coast Urological Medical Group</td>
</tr>
<tr>
<td></td>
<td>23961 Calle De La Magdelenia</td>
</tr>
<tr>
<td></td>
<td>Suite 534</td>
</tr>
<tr>
<td></td>
<td>Laguna Hills CA 92653</td>
</tr>
<tr>
<td>6097</td>
<td>D. Russell Locke, MD</td>
</tr>
<tr>
<td></td>
<td>Mark Dersch, MD</td>
</tr>
<tr>
<td></td>
<td>Ira Klimberg, MD</td>
</tr>
<tr>
<td></td>
<td>Urology Center of Florida</td>
</tr>
<tr>
<td></td>
<td>3201 Southwest 34th St.</td>
</tr>
<tr>
<td></td>
<td>Ocala FL 34474</td>
</tr>
<tr>
<td></td>
<td>924 North Highway 27/441</td>
</tr>
<tr>
<td></td>
<td>Lady Lake FL 3215</td>
</tr>
</tbody>
</table>
### Study 154 – 118/Complicated UTI:

<table>
<thead>
<tr>
<th>PRINCIPAL INVESTIGATORS</th>
<th>SUBINVESTIGATORS</th>
<th>STUDY SITES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ira Klimberg, MD</td>
<td>Mark Dersch, MD</td>
<td>The Urology Center of Florida Inc.</td>
</tr>
<tr>
<td></td>
<td>D. Russell Locke, MD</td>
<td>3201 Southwest 34th St.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ocala, FL 34474</td>
</tr>
<tr>
<td>5133</td>
<td>Perry Garber, MD</td>
<td>Independent Research Nurses Inc.</td>
</tr>
<tr>
<td>Dennis Mikolich, MD</td>
<td>Jacques Susset, MD</td>
<td>400 Reservoir Ave.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Providence, RI 02907</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scandinavian Home Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1811 Broad St.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cranston, RI 02905</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Morgan Health Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>80 Morgan Ave.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Johnston, RI 02919</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Heritage Hills Nursing Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>80 Douglas Pike</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smithfield, RI 02917</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tockwotton Home</td>
</tr>
<tr>
<td></td>
<td></td>
<td>180 George M. Cohan Memorial Blvd.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Providence, RI 02093</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oak Hill Nursing Home</td>
</tr>
<tr>
<td></td>
<td></td>
<td>544 Pleasant St.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pawtucket, RI 02860</td>
</tr>
<tr>
<td>5143</td>
<td>Thomas Bianchi, MD</td>
<td>100 Highland Ave., Suite 100</td>
</tr>
<tr>
<td>Jimmy Durden, MD</td>
<td>Patrick Bianchi, MD</td>
<td>Providence, RI 02906</td>
</tr>
<tr>
<td></td>
<td>F. Keith Bufford, Jr., MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrew Hughes, MD</td>
<td>Community Medical Arts Center</td>
</tr>
<tr>
<td></td>
<td>Michael Peaden, MD</td>
<td>875 Friendship Rd.</td>
</tr>
<tr>
<td></td>
<td>Melvin Russell, MD</td>
<td>Tallahassee, FL 32306</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tallahassee Family Care</td>
</tr>
<tr>
<td></td>
<td></td>
<td>115 Herren Hill Rd.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tallahassee, AL 32307</td>
</tr>
<tr>
<td>5630</td>
<td>James Borden, MD</td>
<td>Southwest Florida Urologic Associates</td>
</tr>
<tr>
<td>Ronald Castellanos, MD</td>
<td>Paul Breton, MD</td>
<td>12651 Whitehall Dr.</td>
</tr>
<tr>
<td></td>
<td>William Evans, MD</td>
<td>Ft. Myers, FL 33907</td>
</tr>
<tr>
<td></td>
<td>Ronica Kluge, MD</td>
<td>Clinical Physiology Associates</td>
</tr>
<tr>
<td></td>
<td>Sergio Mather, MD</td>
<td>Clinical Study Center</td>
</tr>
<tr>
<td></td>
<td>David Michie, PhD</td>
<td>4110 Center Pointe Dr., Suite 219</td>
</tr>
<tr>
<td></td>
<td>Jasper Rizzo, DO</td>
<td>Ft. Myers, FL 33916</td>
</tr>
<tr>
<td></td>
<td>Mary Yankaskas, MD</td>
<td>Gulfshore Obstetrics and Gynecology</td>
</tr>
<tr>
<td></td>
<td>Stephen Zeilner, MD</td>
<td>12631 Whitehall Drive</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ft. Myers, FL 33907</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Southwest Florida Urologic Associates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>507 Del Prado Boulevard</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cape Coral, FL 33990</td>
</tr>
</tbody>
</table>
Internal Medicine Associates
2675 Winkler Ave., Suite 300
Ft. Myers, FL 33901

Grandview Medical Research Inc.
711 Lawn Ave., Bldg. 1

Grandview Hospital
700 Lawn Ave.
Sellersville, PA 18960

Pennridge Urological Associates
670 Lawn Ave.
Sellersville, PA 18960

Infections Limited PS
1624 South 1 St. #402
Tacoma, WA 98405

Bel Air Nursing Home
630 S. Pearl
Tacoma, WA 98465

Future Healthcare Research Center
Clinical Resources Inc.
754 S. Cleveland Ave. #200
Mogadore, OH 44260

Barberton Citizens Hospital
165 Fifth St. NE
Barberton, OH 44203

Urological Assoc.of Southern Arizona, PC
5000 E. Eckerson, Suite 106
Tucson, AZ 85712

Jackson Foundation/Physicians Plus
20 S. Park St.
Madison, WI 53715

Physicians Plus Medical Group
345 W. Washington Ave.
Madison, WI 53703

Clinic for Male Wellness, Inc.
120 N. Eagle Creek Medical Plaza
Suite 121
Lexington, KY 40509
<table>
<thead>
<tr>
<th>ID</th>
<th>Investigator, MD</th>
<th>Phone Number/Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>5687</td>
<td>John Aldridge, MD</td>
<td>Mississippi Urology Clinic</td>
</tr>
<tr>
<td></td>
<td>W. Meredith Bradford, MD</td>
<td>1421 N. State St., Suite 403</td>
</tr>
<tr>
<td></td>
<td>Thomas Fenter, MD</td>
<td>Jackson, MS 39202</td>
</tr>
<tr>
<td></td>
<td>James Keeton, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wafford Merrell, MD</td>
<td>971 Lakeland Dr., Suite 657</td>
</tr>
<tr>
<td></td>
<td>Robert Myers, MD</td>
<td>Jackson, MS 39216</td>
</tr>
<tr>
<td></td>
<td>Joe Ross, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Charles Scruggs, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Charles Secrest, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Scott Kelly, MD</td>
<td>Alabama Urology Assoc., PC</td>
</tr>
<tr>
<td>5688</td>
<td>Simon Mirelman, MD</td>
<td>2022 Brookwood Medical Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brookwood Assoc., Suite 305</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Birmingham, AL 35209</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Childersburg Medical Surgical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>34011 Highway 280 East</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Childersburg, AL 35044</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5689</td>
<td>Paul Brower, MD</td>
<td>South Coast Urological Medical Group</td>
</tr>
<tr>
<td></td>
<td>Steven Rudy, MD</td>
<td>23961 Calle De La Magdelena, Suite 534</td>
</tr>
<tr>
<td></td>
<td>J. Bradley Taylor, MD</td>
<td>Laguna Hills, CA 92653</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>South Coast Urological Medical Group</td>
<td></td>
</tr>
<tr>
<td></td>
<td>31862 Coast Highway, Suite 302</td>
<td>South Laguna, CA 92077</td>
</tr>
<tr>
<td></td>
<td>South Coast Urological Medical Group</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1720 S. Orange Ave., Suite 401</td>
<td>Central Florida Medical Research Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orlando, FL 32806</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of Central Florida</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UCF Student Health Services</td>
<td></td>
</tr>
<tr>
<td>5681</td>
<td>Abdullah Iravani, MD</td>
<td>400 Central Florida Blvd., Bldg. 27</td>
</tr>
<tr>
<td></td>
<td>John Langton, MD</td>
<td>Central Florida Medical Research Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orlando, FL 32816</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>West Orange Manor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>122 E. Division St.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Winter Garden, FL 34777</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orlando Health Care Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2000 N. Semoran Blvd.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orlando, FL 32907</td>
</tr>
</tbody>
</table>